Authors:
LECESNE A
CHABOT G
BERILLE J
LUCAS C
BAUD M
GOUYETTE A
MARTY M
LECHEVALIER T
Citation: A. Lecesne et al., PHASE I-II AND PHARMACOKINETIC STUDY OF A NEW FOTEMUSTINE SCHEDULE INADVANCED NON-SMALL-CELL LUNG-CANCER, Lung cancer, 13(1), 1995, pp. 69-78
Citation: A. Lecesne et al., IMPACT OF CHEMOTHERAPY ON SURVIVAL IN LOCALLY ADVANCED NONSMALL CELL LUNG-CANCER - THE GUSTAVE-ROUSSY EXPERIENCE, Lung cancer, 12, 1995, pp. 79-85
Authors:
BELLI L
LECHEVALIER T
GOTTFRIED M
ADAMS D
RUFFLE P
LECESNE A
TETE L
PELLAECOSSET B
Citation: L. Belli et al., PHASE I II STUDY OF PACLITAXEL PLUS CISPLATIN AS FIRST-LINE CHEMOTHERAPY FOR ADVANCED NON-SMALL-CELL LUNG-CANCER - PRELIMINARY-RESULTS/, Seminars in oncology, 22(6), 1995, pp. 29-33
Citation: T. Lechevalier et al., DEALING WITH INITIAL CHEMOTHERAPY DOSES - A NEW BASIS FOR TREATMENT OPTIMIZATION IN LIMITED SMALL-CELL LUNG-CANCER, Bulletin du cancer, 82, 1995, pp. 24-28
Authors:
RIVIERE A
LECESNE A
BERILLE J
BAIO S
LECHEVALIER T
Citation: A. Riviere et al., CISPLATIN-FOTEMUSTINE COMBINATION IN INOPERABLE NONSMALL CELL LUNG-CANCER - PRELIMINARY-REPORT OF A FRENCH MULTICENTER PHASE-II TRIAL, European journal of cancer, 30A(5), 1994, pp. 587-590
Authors:
ROITHMANN S
PIQUE C
LECESNE A
DELAMARRE L
PHAM D
TURSZ T
DOKHELAR MC
Citation: S. Roithmann et al., THE OPEN READING FRAME-I (ORF-I) ORF-II PART OF THE HUMAN T-CELL LEUKEMIA-VIRUS TYPE-I X-REGION IS DISPENSABLE FOR P40(TAX), P27(REX), OR ENVELOPE EXPRESSION/, Journal of virology, 68(5), 1994, pp. 3448-3451